pharma news

News

Where others missed, AZ's IL-33 drug hits the mark in COPD

AZ's IL-33 inhibitor tozorakimab hits the mark in two late-stage COPD trials, raising the prospects of a class that has had some failures in the past.

News

Touchdown for Rocket as its first gene therapy gets US okay

Rocket Pharma has won FDA approval for the first gene therapy for LAD-I, a devastating genetic disorder causing severe vulnerability to infections.

News

Novartis snaps up food allergy firm Excellergy for $2bn

Novartis has signed its second M&A deal in the space of a week, pledging to pay up to $2 billion to acquire US food allergy drug developer Excellergy.

News

Wave's stock wavers on obesity drug data

Wave Life Sciences has said new clinical trial results with its non-incretin therapy for weight loss are positive – but investors don't seem to agree.

News